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Introduction
Current genetic models of disease
Thousands of human diseases are known to have a genetic 
component, although the penetrance of this effect and the 
contribution of environmental influences are highly vari-
able. Recent advances in genotyping and DNA sequenc-
ing have facilitated the studies of familial inheritance, de 
novo mutations (Deciphering Developmental Disorders 
2015; Wright et  al. 2015) and numerous genome-wide 
association studies (GWAS) (Visscher et  al. 2012), which 
have begun to identify the genetic loci underlying many of 
these diseases. However, despite such advances in human 
genetic analysis, unravelling the causative lesions, under-
standing the underlying molecular and cellular mechanisms 
and developing ways to prevent or treat such diseases still 
require experimental models (Nishizaki and Boyle 2016).
The evolutionary conservation of mammalian genomes, 
especially in protein coding sequence, has enabled the use 
of many animal models such as mice, rats and non-human 
primates for studying the effects of genetic lesions upon 
molecular, cellular, physiological and behavioural pheno-
types. This has led to many important insights into disease 
biology, and their importance in such studies is undeniable. 
Despite such conservation of function, given the last com-
mon ancestor of human and mouse was around 100  mil-
lion years ago (Mouse Genome Sequencing Consortium 
et al. 2002), it is unsurprising that there are also differences 
between these organisms. Around 20% of genes in humans 
lack an identifiable one-to-one orthologue in mouse (Mouse 
Genome Sequencing Consortium et al. 2002), and the num-
ber of paralogs within an organism is often different, many 
of which have diverged to provide subtly different functions 
(Gabaldon and Koonin 2013). Equally, even apparently 
Abstract The advent of human-induced pluripotent stem 
cell (hiPSC) technology has provided a unique opportu-
nity to establish cellular models of disease from individual 
patients, and to study the effects of the underlying genetic 
aberrations upon multiple different cell types, many of 
which would not normally be accessible. Combining this 
with recent advances in genome editing techniques such 
as the clustered regularly interspaced short palindromic 
repeat (CRISPR) system has provided an ability to repair 
putative causative alleles in patient lines, or introduce dis-
ease alleles into a healthy “WT” cell line. This has enabled 
analysis of isogenic cell pairs that differ in a single genetic 
change, which allows a thorough assessment of the molecu-
lar and cellular phenotypes that result from this abnormal-
ity. Importantly, this establishes the true causative lesion, 
which is often impossible to ascertain from human genetic 
studies alone. These isogenic cell lines can be used not 
only to understand the cellular consequences of disease 
mutations, but also to perform high throughput genetic and 
pharmacological screens to both understand the underlying 
pathological mechanisms and to develop novel therapeu-
tic agents to prevent or treat such diseases. In the future, 
optimising and developing such genetic manipulation tech-
nologies may facilitate the provision of cellular or molecu-
lar gene therapies, to intervene and ultimately cure many 
debilitating genetic disorders.
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orthologous genes can play different roles, such as in the 
case of TDP1, which shows a different subcellular locali-
sation in humans and mice, and mutations in which are 
linked to the SCAN1 disorder in humans, but lack a clear 
phenotype in the mouse (Gharib and Robinson-Rechavi 
2011). Additionally, there will clearly always be certain dif-
ferences inherent to a particular species due to their evolu-
tionary adaptation, for instance in cardiac or brain function 
between human and mouse, making it impossible to study 
some human-specific phenotypes in animal models.
One of the surprises of the human genome project 
(Lander et  al. 2001) was that only a relatively small pro-
portion of the genome is protein coding (current estimates 
are around 1.2%) (Pruitt et al. 2009). The remainder of the 
sequence contains many repetitive sequences and trans-
poson remnants, although a further 3–10% of the human 
genome displays evidence of evolutionary conservation, 
implying its functionality (Lunter et  al. 2006). There is 
clearly a role for at least a proportion of this non-coding 
sequence in regulation of gene expression. In fact, more 
than 95% of disease-associated single nucleotide polymor-
phisms (SNPs) lie within the non-coding genome (Maurano 
et  al. 2012). Importantly, such SNPs may be functionally 
relevant, since they are enriched within enhancer regions 
(marked by DNAse hypersensitivity) specific for the dis-
ease-associated tissue (Maurano et al. 2012), and are often 
associated with changes in neighbouring gene expression 
(Degner et al. 2012). It is also beginning to become appar-
ent that such non-coding changes can result in phenotypic 
effects, and be causative in certain diseases (Soldner et al. 
2016). In the context of disease modelling, such sequences 
are much more poorly conserved between organisms than 
protein coding sequences, often making it impossible to 
identify the orthologous region in other species. In this sit-
uation, developing a human model of disease becomes even 
more relevant.
Primary cell cultures from human patients are an invalu-
able resource to study the molecular and cellular effects of 
particular mutations, but there are many limitations to this 
strategy, not least in the inaccessibility of certain tissues, 
for instance the brain. Even if the tissue is accessible, such 
cells are often challenging to culture, and cannot be main-
tained for extended periods of time, making genetic engi-
neering difficult. Equally, many primary cultures consist 
of heterogeneous cell populations that are not necessarily 
consistent between samples, often complicating analysis. 
Although many immortalised cell lines also exist, these 
necessarily contain genetic aberrations that enable their 
continued culture, and therefore do not represent a highly 
physiological model of disease.
The generation of human embryonic stem cell (hESC) 
lines (Shamblott et al. 1998; Thomson et al. 1998) opened 
up the exciting possibility of using these pluripotent stem 
cells to study the function of differentiated derivative cell 
types. However, due to the technical and ethical difficulties, 
it is not feasible to produce a large number of such lines or 
derive them from patients with diseases, limiting their use 
to studies of normal cellular function, or to introduction of 
known engineered genetic changes.
Induced pluripotent stem cells (iPSCs) for disease 
modelling
iPSC technology
The advent of induced pluripotent stem cell (iPSC) tech-
nology (Takahashi et  al. 2007; Takahashi and Yamanaka 
2006) has revolutionised many fields, notably those of dis-
ease modelling and cellular therapeutics due to our ability 
to generate such pluripotent stem cells from essentially any 
human, including those with disease (Avior et  al. 2016). 
Somatic cells can be reprogrammed to a pluripotent stem 
cell state similar to that present in very early embryogen-
esis through transient expression of four transcription fac-
tors (Oct4, Sox2, Klf4 and c-Myc) (Takahashi et al. 2007; 
Takahashi and Yamanaka 2006). Importantly, such cells are 
diploid and karyotypically normal, can self-renew for many 
cell divisions and can be differentiated into a broad range of 
different cell types. These characteristics lend themselves 
to the study of development and cellular function both in 
normal and disease states, and also allow large numbers of 
cells to be produced for high throughput genetic and drug 
screening as well as cell therapy. This has led to the incep-
tion of several large-scale initiatives for deriving iPSCs 
from thousands of normal and diseased patients (California 
Institute for Regenerative Medicine (CIRM), Stem Cells for 
Biological Assays of Novel Drugs and Predictive Toxicol-
ogy (StemBANCC) (Morrison et al. 2015) and the Human-
induced Pluripotent Stem Cell initiative (HiPSCi) (Streeter 
et al. 2016)). Cell lines have been thoroughly characterised 
by for example DNA sequencing, SNP genotyping, RNA 
sequencing and DNA methylation analysis (Soares et  al. 
2014) and can be accessed through cell banks across the 
world (such as the European Collection of Cell Cultures 
(ECACC), the European Bank for induced pluripotent Stem 
Cells (EBiSC) and the Coriell biorepository). These cell 
lines have been derived from individuals with a variety of 
monogenic and polygenic disorders, and provide an invalu-
able resource for studying genetic contributions to human 
disease. They can be used to create personalised models 
of disease, and understand the molecular and cellular phe-
notypes underlying their pathogenesis. Interestingly, since 
cells are reprogrammed to a very early stage of develop-
ment, they can be used to monitor both developmental or 
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differentiation defects as well as the temporal sequence of 
events in the early stages of disease progression.
Considerations for iPSC disease models
When considering use of iPSCs as a disease model, there 
are many important considerations; whether the disease is 
monogenic or polygenic, the penetrance of the mutation, 
the age of onset, whether differentiation into an appropriate 
cell type is possible, and if there is an appropriate pheno-
typic readout at a molecular or cellular level.
Whilst the majority of genetic diseases are due to a small 
contribution from a large number of genes, such poly-
genic disorders are inherently more difficult to study than 
monogenic diseases, since typically both the penetrance 
and severity of the phenotype due to any single mutation 
are lower (Wheeler et al. 2016). This is true of any disease 
model, and our ability to obtain iPSCs from patients with 
and without a disease makes analysis of polygenic disor-
ders such as autism (DeRosa et  al. 2012) or schizophre-
nia (Brennand et  al. 2011) more feasible. However, fur-
ther genetic manipulations to prove the causal alleles (see 
below) become more challenging due to the larger num-
ber of genes involved, smaller phenotypic effects and the 
potential for epistasis between different alleles. As with 
most current models of such diseases, it is often simpler to 
study the effect of a familial form with higher penetrance 
and severity, to identify phenotypes that can then be reca-
pitulated in other forms of the disease.
Equally, it is critical with any iPSC disease model to pin-
point a cell type in which the disease manifests, to be able 
to differentiate effectively into these cells, and to identify 
a molecular or cellular phenotypic readout of the disease 
state. Differentiation protocols are now available to effi-
ciently generate a large variety of lineages, and many oth-
ers are being developed using cocktails of small molecule 
inhibitors or transcription factor overexpression (Cohen 
and Melton 2011; Mertens et  al. 2016; Murry and Keller 
2008). Although such protocols often result in a mixed 
population, purification of the desired cells by for example 
fluorescence-activated cell sorting (FACS) using an appro-
priate marker or reporter gene can be used to enrich for the 
population of interest (Horikiri et al. 2017; Wu et al. 2016a, 
b). Perhaps more critical to the success of any cellular dis-
ease model is the identification of a molecular or cellular 
phenotype that correlates with the disease state. In many 
cases, this can be identified through global gene expression 
profiling of patient and control samples (at the RNA or pro-
tein level), and identification of a profile of gene expression 
changes that correlate with disease. Alternatively, other 
cellular phenotypes can be employed such as functional 
readouts of cell activity (e.g. electrophysiological measure-
ments of neurons, activity of cardiac muscle or response of 
macrophages to pathogen stimulation), more generic cellu-
lar features such as cell shape, subcellular localisation of 
particular marker genes, endocytic trafficking, or cellular 
responses to their environment (e.g. secretion or response 
to signals, sensitivity to drugs or other cellular stresses). In 
some cases, such as mutations in SCN5A that are linked 
to cardiac arrhythmia and long QT syndrome, these phe-
notypes are predictable and directly related to the disease 
(Davis et  al. 2012). However, in other diseases such as 
autism spectrum disorders (ASD) (DeRosa et al. 2012) or 
schizophrenia (Brennand et  al. 2011) which are classified 
by complex behavioural phenotypes, how well these corre-
late to any underlying molecular or cellular changes, and 
to what extent these are causative in the disease are still 
largely unexplored.
Another important consideration with the use of iPSCs 
in disease modelling is that these cells and their differen-
tiated derivatives often resemble those of foetal origin 
(Hrvatin et al. 2014), and therefore the age of onset of any 
disease becomes relevant. Indeed, iPSC-derived neurons 
initially differentiate into an immature state and can require 
months in culture before they become electrophysiologi-
cally active. This complicates analysis of diseases such 
as neurodegeneration which only show effects late in life. 
Several strategies exist to circumvent this issue, at least to 
some extent. Often, rare, early-onset, familial mutations are 
associated with many normally polygenic late-onset dis-
eases, and these can be useful models to study phenotypes 
associated with such diseases in general. One example of 
this is a triplication of a large region including the SNCA 
locus that leads to an early-onset Parkinson’s disease phe-
notype (Devine et  al. 2011). iPSC-derived dopaminergic 
neurons derived from these patients show molecular phe-
notypes characteristic of the disease, suggesting that such 
pathological events can be detected and monitored (Chung 
et al. 2013). An alternative strategy is to accelerate ageing 
or disease progression using stressors such as rotenone, 
MG-132 or concanamycin A (Cooper et al. 2012; Nguyen 
et al. 2011), or through expression of Progerin, a truncated 
form of lamin A that is associated with Hutchinson–Gilford 
progeria syndrome, a premature ageing disorder (Miller 
et al. 2013). Whilst Progerin expression has been shown to 
accelerate cellular markers of ageing such as DNA damage 
and heterochromatic chromatin modifications (Miller et al. 
2013), it is still unclear to what extent such treatments fully 
recapitulate the effects of old age.
Importantly, it is perhaps unsurprising that even with 
late-onset diseases, there are pathogenic changes occurring 
at an early point in disease progression that are detectable 
in iPS models, and can be reverted by pharmacological 
intervention (reviewed in (Avior et  al. 2016)). Arguably, 
these early changes are more critical in terms of under-
standing and treating the disease. Studying such effects 
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would facilitate discovery of biomarkers that identify those 
patients at risk and allow development of strategies to ena-
ble early, targeted intervention to prevent the disease. This 
is particularly important in situations such as neurodegen-
eration where, by the time patients present with the dis-
ease, they often have irreparable damage such as the loss of 
neurons, and for whom therapeutic intervention at this late 
stage may not be possible.
Limitations and developments
Whilst the benefits of iPSC technology are undeniable, 
there are some limitations in their use for modelling of 
certain disease states. Such in vitro models have immense 
power in terms of scalability, and being able to apply tech-
niques such as high throughput genetic or pharmacological 
screening that would not be possible or be technically diffi-
cult in an in vivo setting (Fig. 1). However, they are limited 
in their ability to recapitulate complex tissue architecture 
both in terms of the complexity of cell types as well as their 
spatial organisation, making analysis of many physiologi-
cal or system-level phenotypes challenging. Highly defined 
co-culture systems can be beneficial in some situations, for 
instance where the effects are non-cell autonomous, or rely 
on cell–cell signalling. This has been successfully applied 
to modelling of the effects of SOD1 mutation in glial 
cells on motor neuron survival in cells derived from ALS 
patients (Di Giorgio et al. 2007, 2008).
Exciting developments in terms of three-dimensional 
culture systems such as intestinal (Dekkers et  al. 2013; 
Schwank et  al. 2013) or cerebral (Lancaster et  al. 2013) 
organoids allow analysis of cell–cell interactions in a more 
complex mixture of cell types with some underlying tissue 
architecture (Huch and Koo 2015; Lancaster and; Kno-
blich 2014; Passier et  al. 2016). Such systems have been 
exploited to uncover cellular phenotypes underlying micro-
cephaly (Lancaster et al. 2013) and cystic fibrosis (Dekkers 
et  al. 2013; Schwank et  al. 2013), respectively. Although 
progress is being made in organ reconstruction of struc-
tures such as the integumentary system is being made (Tak-
agi et al. 2016), it is unlikely that very complex tissues will 
be able to be modelled successfully in vitro at least in the 
near future.
In certain instances, diseases manifest as complex physi-
ological or behavioural phenotypes, which cannot be reca-
pitulated in any in vitro model. An alternative strategy is to 
use xenograft systems in animal models where the endog-
enous organ has been genetically ablated (Kobayashi et al. 
2010; Lee et  al. 2014; Nagashima and Matsunari 2016). 
These may provide an opportunity to analyse such complex 
physiological and system-level phenotypes with human 
patient-derived cells, and potentially provide a source of 
such organs for transplantation in the future. Whilst such 
systems may be important for analysis of certain diseases, 
it is likely that most physiological defects result from inher-
ent underlying molecular or cellular abnormalities. There-
fore, cellular phenotypes such as gene expression changes 
or neuronal electrophysiology will not only help to ascer-
tain the molecular mechanisms underlying complex disease 
phenotypes such as Alzheimer’s disease but also provide 
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Fig. 1  Application of iPS models of disease to high throughput 
screening. Cells derived from patients with disease and healthy con-
trols can be used to generate disease-relevant cell types, which can be 
phenotypically compared with each other. Such cells can be generated 
in sufficient numbers to be able to perform whole genome genetic 
screens to identify molecular and cellular mechanisms of disease and 
therapeutic targets, and also for high throughput drug screening to 
identify compounds that may be able to revert the disease phenotype. 
Differences between patient-derived and control cells can be used to 
identify potential therapeutic targets or agents
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convenient measures for measuring the effects of genetic or 
pharmacological intervention.
Genome editing in iPSC disease modelling
Importance of genome editing
Many human genetic diseases by their very nature would 
only be expected to show subtle effects on cellular behav-
iour, since those individuals show essentially normal dif-
ferentiation, development and cellular function and only 
present symptoms of disease after birth, in old age, or 
upon exposure to environmental triggers. This alongside an 
inherent variability in both the iPSC derivation process and 
differentiation into specific cell types makes it necessary 
to perform comparisons of many independently derived 
cell lines from multiple healthy and diseased individuals 
in order to detect such subtle changes. This can be amelio-
rated by genetic engineering to introduce or repair putative 
causative alleles to generate isogenic cell line pairs that 
have identical genetic backgrounds, and differ in only a sin-
gle genetic change (Fig. 2). This allows detection of subtle 
phenotypes that would otherwise be masked by variations 
in cellular phenotype due to the different genetic back-
grounds of the donors.
Importantly, such experiments also allow the identi-
fication of the causative lesion that defines the cellular 
phenotype and results in the disease (Nishizaki and Boyle 
2016). This is not possible from comparisons of iPSC lines 
derived from patients with the disease and healthy controls, 
due to the inheritance patterns of linked SNPs. Often sev-
eral SNPs are in linkage disequilibrium (LD) with each 
other, and as such are always inherited together (Weiss 
and Clark 2002) (Fig. 3). Deciphering which of these are 
causative is therefore a challenge, and although it is pos-
sible to infer some information from their position relative 
to known important genomic features (e.g. protein coding 
sequence, DNAse hypersensitive sites, etc.), experimen-
tally identifying the important genetic aberration is still not 
trivial. Genome editing allows the attractive possibility of 
either repairing the putative causative lesions in patient-
derived cells, or introducing them in cells derived from 
healthy individuals (Fig. 2), to unambiguously identify the 
mutations involved in the disease phenotype.
Genome editing has been used in many examples 
(Table 1) to create isogenic pairs of cell lines, and this has 
been successful in both validating the causative lesion and 
allowing greater sensitivity for phenotypic detection. The 
importance of such studies is undeniable, and the usage of 
such isogenic lines in iPS disease modelling will undoubt-
edly increase in the coming years.
CRISPR genome editing technology
Recent improvements in genome editing have vastly 
increased our ability to introduce such delicate defined 
mutations within the genomes of human cells. These are 
based on designer site-specific nucleases that introduce a 
double-strand break (DSB) at a desired site in the genome, 
which is then repaired by the cell, and can be utilised to 
introduce a variety of different genetic changes at this site. 
Most recent work focuses on the clustered, regularly inter-
spaced short palindromic repeats (CRISPR) system and the 
use of the RNA-guided CRISPR-associated 9 (Cas9) endo-
nuclease (Cho et  al. 2013; Cong et  al. 2013; Jinek et  al. 
2012, 2013; Mali et  al. 2013), predominantly due to the 
simplicity by which this can be reprogrammed to bind to 
millions of sites within the genome. This system relies on a 
short guide RNA molecule to direct its specificity, through 
base pairing of its first 20 nt with the corresponding DNA 
sequence in the genome (Jinek et al. 2013). The only lim-
itation to the targeting is a requirement for a protospacer 
adjacent motif (PAM) sequence adjacent to the target site, 
which is not present in the guide RNA, but is recognised by 
the Cas9 protein. In the case of the most widely used Strep-
tococcus pyogenes Cas9 protein, this is NGG, which in a 
genome with an even base distribution and composition 
should occur every 8 bp. However, should this be a limita-
tion, orthologues of Cas9 in other species have been discov-
ered with alternative PAM requirements (Hou et al. 2013; 
Ran et al. 2015; Zetsche et al. 2015) and recently, protein 
engineering has been used to alter the PAM sequences of 
several Cas9 nucleases (Kleinstiver et al. 2015a, b) (as dis-
cussed elsewhere in this issue).
Introduction of a DSB into the genome allows many 
different types of genetic manipulation. Usually, this 
DNA damage is repaired by one of two major pathways, 
non-homologous end joining (NHEJ) that performs non-
templated ligation of the free DNA ends, and homology 
directed repair (HDR) that utilises homologous DNA to 
direct a precise repair (Bibikova et  al. 2003; Shrivastav 
et al. 2008). Both of these can be exploited for making site-
specific genetic mutations. Repair through NHEJ or related 
pathways such as microhomology mediated end joining 
(MMEJ) can result in insertions or deletions (indels) of sev-
eral nucleotides at the DSB that can be used for instance to 
introduce a frameshift in protein coding sequence, result-
ing in a null allele. If two DSBs are made simultaneously, 
the NHEJ machinery can also ligate the wrong termini 
together, resulting in deletions, inversions or translocations 
(Torres et al. 2014; Xiao et al. 2013; Park et al. 2016). In 
the context of more defined changes to the DNA such as 
introduction of SNPs, HDR pathways can be utilised by 
providing an excess of a desired sequence, resulting in 
this being used in preference to the sister chromatid as the 
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template for repair. Introduction of mutations can be highly 
efficient, especially for NHEJ-based pathways, which gen-
erally predominate in most cells including human iPSCs, 
and can approach 80–90% in the best examples.
This efficiency, coupled with the simplicity of construct-
ing guide RNAs from synthetic oligonucleotides, which are 
amenable to being produced in both multi-well plates or in 
larger pools of tens of thousands, has allowed both arrayed 
(Hultquist et  al. 2016) and pooled screening strategies 
(Gilbert et  al. 2014; Koike-Yusa et  al. 2014; Konermann 
et  al. 2015; Shalem et  al. 2014; Wang et  al. 2014a, b) to 
be conceived. This provides the exciting prospect of for-
ward genetic screening in human patient-derived cell lines 
to identify potential therapeutic targets and to better under-
stand molecular and genetic basis of disease (Fig. 1).
Genome editing technologies also have the potential in 
the future to be utilised as a therapeutic agent in their own 



























Fig. 2  Importance of genome editing in iPS disease modelling. 
iPSCs can be derived from healthy (blue) and disease (orange) 
patients, and after differentiation into an appropriate cell type, com-
parison of molecular or cellular phenotypes can be made. To mini-
mise variability due to genetic background, genome editing can be 
used to either correct patient-derived cells (dark blue) or to introduce 
putative causative lesions into cells derived from healthy individu-
als (purple). This leads to isogenic pairs of cell lines (purple box or 
orange box) that identify the true impact of the engineered change on 
the cellular phenotype
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disease (Cox et al. 2015). Such reagents could not only be 
applied in an in  vivo context, but also to repair causative 
lesions in patient-derived iPSCs that could subsequently 
be used to generate specific cell types to use as cellular 
therapies. Such strategies have shown significant promise 
in some cases, for example in the treatment of a chemi-
cally induced primate model of Parkinson’s disease through 
injection of autologous iPSC-derived dopaminergic neu-
rons (Emborg et  al. 2013; Hallett et  al. 2015). Therapies 
for HIV (Tebas et al. 2014) and cancer (Fesnak et al. 2016) 
involving genome editing are already in clinical trials, and 
the next few years will likely herald exciting developments 
in this area of somatic gene therapy.
Strategies for genome editing in iPS models 
of disease
There are two main strategies for using genome editing 
techniques in iPSC models of disease. The first involves 
repairing a pre-existing, presumed causative allele from an 
iPSC line derived from a patient with the disease (Fig. 2, 
isogenic pair 1). This establishes whether this particular 
genetic change contributes to the disease phenotype, but 
does not provide any information about whether it is suffi-
cient to cause disease. It also has the substantial benefit that 
the patient-derived cell line would be expected to express 
whatever cellular or molecular phenotype that is causing 
the disease, and therefore reversion of this phenotype in the 
edited line can be used as a readout. The second strategy 
involves taking an iPSC line from a healthy patient, and 
introducing a putatively important lesion (Fig. 2, isogenic 
pair 2). This is perhaps a more stringent assay, since it 
establishes whether this single genetic change is sufficient 
to cause the disease phenotype, since it removes it from the 
genetic background of the diseased individual. However, if 
no effect is seen on the molecular or cellular phenotype of 
interest, it is not possible to infer whether this allele con-
tributes to the disease. Equally, the effect of genetic back-
ground can be investigated in this manner by introducing 
putative causative lesions into a panel of “WT” iPSCs 
established from healthy donors from diverse genetic 
ancestries.
These strategies are clearly complementary to each 
other, and can provide information on potential epistatic 
interactions with other alleles present in specific genetic 
backgrounds. It is also worth considering that modification 
of a “WT” cell line is often simpler technically, since both 
the genome editing and subsequent downstream differen-
tiation and analysis can be optimised for a particular cell 
type. Additionally, the “WT” cells can be thoroughly char-
acterised beforehand, and different genetically edited lines 
involved in the same disease can be directly compared. In 
the case of patient-derived cells, each cell line will behave 
somewhat differently, and therefore it is often more dif-
ficult to perform such manipulations, especially at higher 
throughput.
When designing such an experiment, it is also impor-
tant to consider the inherent variability between patients as 
well as in the processes of both reprogramming of somatic 
cells to iPSCs and differentiation into particular cell types. 
It has been suggested that at least part of this heterogeneity 
results from an “epigenetic memory” of the DNA methyla-
tion signature of the cell type from which the iPSCs were 
derived (Kim et al. 2010), which may impact upon the phe-
notypes observed, or the ability to differentiate into particu-
lar lineages (Bar-Nur et  al. 2011). Reassuringly however, 
recent studies looking at the origin of heterogeneity within 
Fig. 3  Linkage disequilibrium 
(LD) makes identification of 
causative SNPs challenging. In 
a typical region of the human 
genome, many SNPs (orange 
box) are in strong LD with the 
tag SNP (red) identified by a 
GWAS study. Genome editing 
can be used to identify the 
causative lesion from within 
this LD block. LD is measured 
as R-squared values between 
pairs of SNPs, and indicated on 
the heatmap
LD - r-squared
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25 iPSC lines have demonstrated that, at least at the tran-
scriptional level, the majority of variation is due to genetic 
background as opposed to any epigenetic contribution 
(Rouhani et  al. 2014). In order to account for such inher-
ent variability, it is necessary to analyse multiple (typically 
at least three) patients, each with independent iPSC deriva-
tions, clonally derived lines and differentiation experiment, 
which rapidly increases the number of samples that need to 
be analysed (Fig. 2). The number of each that are required 
depends on multiple factors including the magnitude of the 
phenotype and the degree of variability within a particular 
differentiation protocol, but it is unwise to rely at any stage 
on the results from a single experiment.
Whilst genome editing can be very effectively used 
to reduce the variability between patients, the process of 
genome editing itself can introduce artefacts from both 
off-target mutagenesis (Cradick et al. 2013; Fu et al. 2013; 
Veres et al. 2014) and clonal variability within a particular 
iPSC line. One method for controlling the variability intro-
duced by the genome editing process is by re-introducing 
the disease mutation in the genetically corrected patient 
line. Similarly, introducing mutations into a consistent 
“WT” line can reduce the variability between patients and 
during iPSC derivation. The experimental strategy will 
depend on the specific question that is being addressed, 
but these criteria should be taken into account in order to 
maximise sensitivity for phenotypic changes, and minimise 
workload.
Genome editing methods
Numerous strategies exist for genome editing using 
CRISPR, predominantly differing in the method of deliv-
ery of the Cas9 and guide RNA components. Inducible 
Cas9 transgenes (Gonzalez et  al. 2014), DNA plasmids 
(Ding et  al. 2013a, b; Kwart et  al. 2017; Merkert et  al. 
2014; Miyaoka et  al. 2016, 2014; Yang et  al. 2013) or 
Cas9 ribonucleoprotein (RNP) complexes (Kim et  al. 
2014; Liang et  al. 2015; Lin et  al. 2014; Richardson 
et  al. 2016) have all been successful in introducing tar-
geted mutations in hiPS cells (reviewed in more detail 
in Merkert and Martin 2016; Santos et  al. 2016). The 
choice of system depends on multiple factors including 
the importance of off-targeting, the type of repair neces-
sary (single nucleotide changes or indel mutations) and 
prior knowledge of optimal delivery methods into a par-
ticular cell line. However, our preference is for delivery 
of RNPs composed of recombinant, bacterially expressed 
Cas9 protein and synthetic RNA oligos corresponding to 
the CRISPR RNA (crRNA) and trans-activating CRISPR 
RNA (tracrRNA) components of the system. This has 
many advantages over other systems since the RNP 
complex is immediately active, when the concentration 
of any donor HDR template is the highest and is rapidly 
degraded over a period of around 12 h (Kim et al. 2014), 
reducing the potential for off-target mutagenesis and re-
targeting after successful HDR. The lack of DNA plas-
mids also eliminates any chances of non-specific integra-
tion of DNA vectors into the genome.
Another important consideration is to minimise off-tar-
get mutagenesis, the extent of which is still debatable in 
the field, and likely depends on the exact system used to 
introduce the CRISPR reagents (Cradick et  al. 2013; Fu 
et al. 2013; Veres et al. 2014). What is clear is that some 
mismatches between the guide RNA and target DNA 
can be tolerated, and the degree to which they impact on 
endonuclease activity depends on their position within 
the sequence, with those nucleotides closer to the PAM 
sequence playing a more critical role in target recognition 
(Hsu et al. 2013). Careful design of crRNA target sites to 
avoid off-targets of less than 3 mismatches can be readily 
achieved using a variety of online tools and will certainly 
minimise any potential problems. Methods for improving 
specificity have been developed using either pairs of Cas9 
enzymes each of which is unable to generate a DSB alone 
(Guilinger et al. 2014; Ran et al. 2013; Tsai et al. 2014), 
truncated guide RNAs (Fu et  al. 2014) or protein engi-
neering of Cas9 to improve specificity (Kleinstiver et al. 
2016; Slaymaker et  al. 2016). Some of these strategies 
including the double nickase approach (Ran et al. 2013) 
have been successfully used in hiPS cells (Eggenschwiler 
et al. 2016; Wu et al. 2016b), although these systems will 
never remove the potential for off-target mutations com-
pletely. Therefore at least in the case of disease models, 
where a small number of lines are produced, it is also 
possible to sequence the putative off-target sites (or even 
the whole genome), generate cell lines with independent 
guides each of which would have a different set of off-
targets, or perform another round of genome engineering 
to repair the introduced genetic change.
Any such manipulations generate a mixed popula-
tion of cells with different genotypes, and a large pro-
portion of the workload is in clonal growth of cells and 
genotyping them. Thus, strategies for rapid, scalable and 
efficient genotyping are paramount to the success of any 
genome editing experiment. Numerous techniques can be 
employed, either at the DNA, RNA, protein or functional 
level. Often selection strategies begin with PCR amplifi-
cation of regions around the sgRNA target site, and sub-
sequent analysis by restriction enzyme polymorphisms, 
digital PCR (Mock et  al. 2016) and Sanger (Brinkman 
et  al. 2014) or high throughput sequencing (Bell et  al. 
2014). However, the choice of strategy will largely 





Different classes of allele vary in terms of the ease by 
which they can be generated, largely due to the bias of 
repair pathways towards NHEJ, and the resulting indel 
mutations. Gene knockouts are perhaps the simplest to pro-
duce, since such indel mutations can be used to introduce 
frameshifts into protein coding sequence (Fig. 4b), making 
the efficiency of mutagenesis very high. It is important to 
carefully consider the gene structure when designing such 
drug R
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a strategy, since alternative promoters, alternative splicing 
and alternative polyadenylation signals are all critical fac-
tors to consider.
It is important that frameshifts are not made too early 
in the protein coding sequence, since if the open reading 
frame (ORF) is too short, reinitiation at a downstream start 
codon can occur (Zimmer et  al. 1994). The efficiency of 
such reinitiation is dependent on the length of the upstream 
ORF, and is highly inefficient if this is greater than 30–40 
amino acids (Luukkonen et al. 1995). Equally, frameshifts 
should not be introduced too late in the coding sequence. 
Normally premature stop codons are recognised by the 
cell and trigger the process of nonsense mediated decay 
(NMD), which prevents expression of the entire protein 
through mRNA degradation (Hug et al. 2016). However, if 
the premature stop codon is present in the final exon, this 
process does not occur, and a slightly truncated peptide 
will be produced, likely with at least partial functionality 
(Hug et al. 2016). In order to obtain a complete knockout 
allele, it is therefore optimal to target a constitutive exon at 
least 30–40 amino acids into the protein coding sequence 
that is not in the final exon. Even in this situation, a com-
plete knockout cannot be guaranteed, since NMD does not 
always act efficiently, and aberrant splicing can occur to 
reconstitute at least part of the protein function. Thus, anal-
ysis of protein expression is an important aspect to consider 
with such mutations.
Many other strategies exist, such as removal of constitu-
tive exons through NHEJ-mediated deletions with pairs of 
guide RNAs flanking these exons (Liu et al. 2016a, b), or 
using a homology construct that guides precise exon dele-
tion of one allele (Fig.  4a), coupled with indel mutations 
on the other. These systems can also be used to make larger 
deletions to recapitulate for instance copy number variants 
(CNVs), which could be informative in certain cases. In all 
cases, it is also important to consider whether the knock-
out of the gene will be lethal at a cellular level, in which 
case conditional knockout by for instance flanking constitu-
tive exons with recombinase sites, or conditional by inver-
sion (COIN) or FLIP strategies (Economides et  al. 2013; 
Andersson-Rolf et  al. 2017) may be beneficial (Fig.  4c). 
Inducible CRISPR systems can also be employed to restrict 
mutations to particular points in time (Bertero et al. 2016), 
and may be helpful in certain situations.
Single nucleotide polymorphisms
In many cases, genetic changes identified from familial 
inheritance studies or GWAS are single nucleotide poly-
morphisms (SNPs). Such mutations often do not result in 
complete loss of protein function, and frequently cause 
missense mutations in protein coding sequence, or changes 
at non-coding regulatory sites that may affect for instance 
transcription factor binding.
In order to introduce such delicate changes to the 
genome, it is necessary to employ the HDR pathway of 
DNA repair, making this process less efficient in general 
than simple gene knockouts (Fig. 4d). Templates for DNA 
repair can be supplied as either double-stranded DNA 
plasmids with approximately 500–1000  nt of homology 
either side of the introduced mutation, or more typically 
as chemically synthesised short single-stranded DNA oli-
gonucleotides (ssODN) of 100–200  nt in length. The lat-
ter are simple to design and synthesise and have a compa-
rable efficiency of HDR to longer dsDNA fragments due 
to the higher recombinogenic activity of ssDNA (Chen 
et  al. 2015). Although there is substantial variability in 
the absolute efficiencies reported in the literature, we find 
similarly to others that a combination of chemically syn-
thesised crRNA and tracrRNA, recombinant Cas9 protein 
and approximately 100 nt ssODN highly effective for intro-
duction of SNPs (Kim et  al. 2014; Liang et  al. 2015; Lin 
et al. 2014; Niu et al. 2016; Richardson et al. 2016; Song 
et al. 2015). This obviates the need for any cloning or DNA 
manipulation, and all components can be purchased from 
commercial vendors. However, longer homology constructs 
have also been effectively used to introduce point mutations 
in other published reports (Wang et al. 2017; Yusa 2013).
In all cases, it is critical to ensure that upon correct 
HDR, the sgRNA is unable to guide further DSB events 
Fig. 4  Strategies for genome editing using CRISPR/Cas9. a Gene 
knockout—CRISPR-enhanced HDR can be employed to replace a 
critical exon with a selectable drug resistance cassette (drug R), on 
one allele, relying on NHEJ-dependent indels to disrupt the other 
allele. b Gene knockout—A CRISPR-induced DSB can be used to 
efficiently introduce indels on both alleles. c Conditional knockout by 
inversion (COIN)—CRISPR-enhanced HDR can be used to introduce 
a Cre-recombinase invertible cassette, flanked by loxP sites (black tri-
angles) into an artificial intron. This contains a splice acceptor site 
followed by a transcriptional termination signal (pA), so in one ori-
entation it causes premature termination and mutation of the gene. In 
the opposite orientation, splicing occurs around the cassette, allowing 
the normal gene product to be produced from this allele. The second 
allele is disrupted by NHEJ-induced indels as in (a). d SNP introduc-
tion—A CRISPR-induced DSB is used to enhance HDR with a 100–
200 nt ssDNA oligonucleotide repair template (green) to introduce 
small defined changes. e Scarless SNP introduction—A selectable 
marker cassette (drug R, green) is introduced into an intron or non-
functional region along with the SNP of interest, and subsequently 
removed by a further round of HDR, or the piggyBac transposase. f 
Scarless SNP introduction—A SNP of interest is introduced as in D 
along with second site mutations necessary to prevent re-cleavage by 
the Cas9 enzyme. A subsequent second round of editing in a simi-
lar manner corrects the secondary mutations to leave only the SNP 
of interest. g Epigenetic editing—Catalytically dead Cas9 protein is 
used to recruit a variety of enzymatic activities (Enz, green circle) to 
specific sites, leading to transcriptional modulation (both positively 
and negatively), DNA or histone modifications such as DNA methyla-





on the newly modified allele, since these could result in 
further undesirable mutagenesis through NHEJ-mediated 
indels. This ideally requires that the sgRNA is chosen to 
span the SNP of interest. Since the guide RNA can toler-
ate up to three mismatches whilst still retaining the abil-
ity to direct the Cas9 endonuclease to this site, it is often 
necessary or advisable to introduce additional base changes 
outside the SNP of interest to ensure this is the case. For 
SNPs within protein coding genes, this can be achieved by 
introducing silent mutations into the DNA whilst main-
taining its protein coding capacity. Even in this case, there 
may still be a role of such synonymous mutations in protein 
translation efficiency (Quax et al. 2015), exonic transcrip-
tion factor binding (Stergachis et al. 2013) or other as yet 
unknown functions. However, for those changes outside of 
protein coding sequence, it is usually impossible to predict 
the effects of such secondary mutations. This makes it nec-
essary to either perform completely scarless mutagenesis or 
alternatively to create two independent alleles with differ-
ent secondary mutations, which can be used to control for 
the effects of these mutations.
Scarless mutagenesis is possible in some cases where 
the SNP happens to fall within the PAM sequence, or 
within a few nucleotides of the 3′ end of the guide RNA, 
since even single-point mutations at these sites can pre-
vent re-cleavage. However, this is not the case in many 
instances, and certain nucleotides are therefore inaccessi-
ble to such manipulations at least with Streptococcus pyo-
genes Cas9. As mentioned above, orthologues from other 
species (Hou et  al. 2013; Ran et  al. 2015; Zetsche et  al. 
2015) or engineered variants (Kleinstiver et  al. 2015a, b) 
are already increasing the range of potential targets, and 
it is likely that in the future, most SNPs will be amenable 
to manipulation in this manner. Another strategy is to use 
a larger dsDNA donor to introduce a selectable marker 
cassette into a non-functional region neighbouring the 
SNP of interest (Fig.  4e) (Wang et  al. 2017; Yusa 2013). 
This cassette can subsequently be removed either by site-
specific recombinases, or scarlessly by a second round of 
homologous recombination or the piggyBac transposase 
(Wang et al. 2017; Yusa 2013). However, in the latter case, 
there are sequence requirements on where the piggyBac 
sequences can be integrated that may limit the effective-
ness of this strategy (Yusa 2013). A third strategy involves 
a two-step genome editing strategy whereby in the first step 
the desired mutation is introduced alongside secondary 
mutations to prevent recutting, and subsequently, the sec-
ondary mutations are removed by a redesigned guide (or 
alternative Cas9 enzyme) and homology template (Fig. 4f) 
(Paquet et al. 2016; Kwart et al. 2017). However, these lat-
ter strategies involve considerably more complex processes, 
and at least two stages of clonal selection, increasing the 
time and cost of producing each mutation.
An additional strategy which has recently been devel-
oped is the use of Cas9 to recruit cytosine deaminase 
enzymes usually involved in somatic hypermutation in 
immune cells (such as the Apobec and AID enzymes) to 
edit the sequence of the genome without inducing a DSB 
(Hess et al. 2016; Komor et al. 2016; Nishida et al. 2016) 
(Fig.  4g). Whilst this could be informative in terms of 
screening and for certain specific mutations, its general 
application in disease modelling is somewhat limited, since 
only transitions from cytosine to thymine are possible.
Epigenome editing
In addition to genetic manipulations, such as gene knock-
outs or single nucleotide changes, a growing number of 
diseases including cancer (Salarinia et  al. 2016) and neu-
rodegenerative (Gos 2013; Jakovcevski and Akbarian 2012; 
Landgrave-Gomez et  al. 2015) diseases can be driven by 
changes in the epigenome of the cell. This can be both 
in terms of transcriptional levels, or for instance changes 
in DNA methylation patterns that may have more subtle 
effects, e.g. to alter how the cell responds to external sig-
nals. The impact and importance of such changes can be 
assessed by using nuclease-deficient forms of Cas9 fused 
to specific chromatin or DNA modifying factors (Fig. 4g). 
Two point mutations in the Cas9 protein (D10A, H840A) 
render it catalytically inactive, whilst retaining its ability 
to bind to specific DNA sequences. Fusion of domains to 
the Cas9 protein or binding to modified guide RNA scaf-
folds then allow recruitment of specific enzymatic activities 
to desired sites in the DNA (Dominguez et al. 2016; Kon-
ermann et  al. 2013) (Fig.  4g). This has been used exten-
sively to manipulate gene expression both positively using 
transcriptional activation domains such as VP16, Rta, p65 
or HSF1 and negatively by fusion to KRAB, and genome-
wide screens using these reagents have been successfully 
implemented (Gilbert et al. 2014; Konermann et al. 2015). 
Such systems have been used to for instance manipulate 
alpha-synuclein levels both positively and negatively in 
neurons derived from patients with a triplication of the 
SNCA locus, allowing manipulation of SNCA levels in this 
disease model (Heman-Ackah et al. 2016). Equally impor-
tantly, a variety of chromatin modifying activities can also 
be recruited, including the p300 histone acetyltransferase 
(Hilton et al. 2015) or LSD1 histone demethylase (Kearns 
et al. 2015) to activate or inactivate enhancers, the Dnmt3 
DNA methyltransferases (Amabile et  al. 2016; Liu et  al. 
2016a, b; Vojta et al. 2016) or TET1 demethylase (Choud-
hury et al. 2016; Liu et al. 2016a, b; Xu et al. 2016) to add 
or remove DNA methylation marks, or other chromatin 
modifying enzymes such as G9a or SUV39H1 (Snowden 
et al. 2002). These reagents will be important in establish-
ing the role and importance of such epigenetic changes in 
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disease progression either by introducing them into healthy 
cells, or reverting effects observed in disease models.
Conclusions
The recent advances in DNA sequencing technologies have 
led to an ever increasing number of human genetic studies 
that have identified numerous candidate loci that are corre-
lated with many diseases. There is therefore a pressing need 
for simple, robust models of disease that can be applied to 
understand the functionality of such genetic lesions. It is 
clear that the intersection of iPSC and genome editing tech-
nologies will provide powerful tools to study such diseases 
in a human cellular system. The use of a human system 
has many advantages, especially in terms of studying the 
majority of disease-associated mutations that do not reside 
within protein coding genes, and for which conservation 
is not sufficient to allow direct comparisons to be made in 
other organisms. The ability to be able to derive cells from 
multiple patient genotypes and the ability to obtain such 
cell lines from repositories around the world will provide 
invaluable opportunities to investigate the link between 
genotype and phenotype. Genome editing will form an 
essential component of such studies, to revert or introduce 
desired genetic mutations to understand their function by 
comparison with a fully isogenic background (Fig. 2). iPSC 
technologies are also amenable to higher throughput stud-
ies of multiple SNPs, identification of the causative lesions, 
loss- and gain-of-function genetic screens to understand 
disease mechanisms and identify drug targets and high 
throughput drug screening, which are likely to be highly 
informative in the coming years (Fig. 1).
One of the powers of iPSCs is that all of these strategies 
can also be applied to multiple different cell types, although 
it remains to be seen to what extent the results obtained in 
such isolated cell populations recapitulate the effects seen 
in complex human tissues. As differentiation protocols and 
three-dimensional cell culture techniques evolve, this can 
only improve our ability to use such systems to model many 
aspects of human disease. However, such cellular systems 
will always be limited in terms of assaying more complex 
system-level physiological and behavioural phenotypes, 
although xenograft systems may provide one means of 
achieving this in an in vivo context. One of the most impor-
tant aspects of employing iPSC models of human disease is 
therefore in cellular and molecular phenotyping. Whilst for 
many diseases, such phenotypes will be known and predict-
able, for others this will require correlation of the normally 
complex physiological phenotypes seen in disease to the 
underlying molecular and cellular defects. Whilst challeng-
ing, this will also provide invaluable information about the 
pathogenic mechanisms leading to such diseases and novel 
avenues for therapeutic intervention.
The synergy between iPSC and genome editing tech-
nologies will no doubt provide many insights into disease 
mechanisms and therapeutic targets, and enable characteri-
sation and prioritisation of genetic aberrations that cause 
particular diseases. This information coupled with the 
applications of iPSC-derived cell types for cellular thera-
pies and CRISPR-based reagents for in  vivo therapeutics 
offer exciting possibilities for personalised genetic medi-
cines in the not-too-distant future.
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